Although (Royle ex Gordon) is endemic to South Asia, where it grows naturally in pure stands, its growth trajectory in Zambia has not been evaluated. It is estimated that half of the plantation total area is found close to the Copper mine smelters, and the other half is in remote locations approximately 30 km away from the mining activities. Variation in tree growth of non-native forests between these locations in Zambia has been observed, but the causes are unknown. We tested the hypotheses that (i) annual tree-rings are cross-datable, (ii) the signals and noise in the growth ring patterns are modulated by variations in precipitation, temperature, solar radiation, and site conditions. We collected data from 67 trees growing close to the emission source and also in the location 30 km away. Site-specific tree ring-width data was collected and chronology built for . We present ring-width chronology data that may be used to infer the radial growth periodicity of at each site. The re-use potential of the data presented includes developing carbon sequestration, yield, and growth models and assessing forest resilience to climate change. It is also intended to enhance the understanding of tree growth and productivity dynamics of non-native pine species. See the article "Assessing cross-datable distinct annual growth rings in non-native Royle ex Gordon in Zambia" for more information.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503584 | PMC |
http://dx.doi.org/10.1016/j.dib.2021.107447 | DOI Listing |
Mol Neurodegener
September 2023
St Vincent's Clinical School, St Vincent's Hospital Sydney, Faculty of Medicine, University of New South Wales, Darlinghurst, NSW, 2010, Australia.
Background: RNA editing at the Q/R site of GluA2 occurs with ~99% efficiency in the healthy brain, so that the majority of AMPARs contain GluA2(R) instead of the exonically encoded GluA2(Q). Reduced Q/R site editing infcreases AMPA receptor calcium permeability and leads to dendritic spine loss, neurodegeneration, seizures and learning impairments. Furthermore, GluA2 Q/R site editing is impaired in Alzheimer's disease (AD), raising the possibility that unedited GluA2(Q)-containing AMPARs contribute to synapse loss and neurodegeneration in AD.
View Article and Find Full Text PDFRes Pract Thromb Haemost
July 2023
Alfred Hospital, Melbourne, Australia.
Background: Restoring hemostasis in patients on oral anticoagulants presenting with major hemorrhage (MH) or before surgical intervention has changed, with the replacement of vitamin K antagonist (VKA) with direct oral anticoagulants (DOACs).
Objectives: To observe the difference in urgent hemostatic management between patients on VKA and those on DOACs.
Methods: A multicenter observational study evaluated the variation in laboratory testing, hemostatic management, mortality, and hospital length of stay (LOS) in patients on VKA or DOACs presenting with MH or urgent hemostatic restoration.
Intern Med J
August 2023
Department of Haematology, Auckland City Hospital, Auckland, New Zealand.
Background: Rivaroxaban is used increasingly as an oral anticoagulant; however, a specific reversal agent is not currently available in the Australasian setting. There is also variation across international consensus guidelines regarding advice on the management of bleeding.
Aims: To review the real-world management of rivaroxaban-associated major bleeding across the public hospitals of New Zealand's largest city.
Thromb Haemost
July 2022
Department of Haematology, Waitemata District Health Board, Auckland, New Zealand.
Background: The recommended dose of idarucizumab, the specific reversal agent for dabigatran etexilate, is 5 g. However, published data showed biochemical reversal after an initial 2.5 g dose.
View Article and Find Full Text PDFThromb Res
November 2021
Department of Clinical Haematology, Monash Medical Centre, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Melbourne, Australia.
Background: Treatment of low-risk patients with isolated symptomatic distal deep vein thrombi (IDDVT) is uncertain.
Objective: assess whether two weeks of therapeutic anticoagulation is efficacious/safe for IDDVT.
Primary Outcome: symptomatic three-month venous thromboembolism (VTE) incidence in the two-week anticoagulation group.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!